Congress will weigh this year whether to continue spending billions of dollars on antidotes for attacks seen as relatively unlikely, but potentially devastating.
Lawmakers helped to establish Project Bioshield in 2004 to incentivize otherwise unprofitable work on treatments for exotic possible terrorism tools, such as anthrax and botulinum toxin. In coming months, though, the decade-old initiative could face unprecedented scrutiny of its funding, in part due to a dearth of chemical, biological, radiological and nuclear attacks in the United States since its launch, says a newly published Congressional Research Service report.
“Congressional policymakers could decide not to fund Project Bioshield,” analyst Frank Gottron said in the assessment. “Given the continued absence of any [WMD] terrorist attacks in the United States since 2001, [they] could deem that the perceived risk of an attack no longer justifies [the] continued investment.”
“Alternatively, policymakers could deem other, more conventional, countermeasure procurement methods sufficient or more efficient than Project Bioshield and redirect funding to those programs,” Gottron wrote.
Four experts describe an emergency-response system in dire need of repair – and what it will take to fix it.
DHS OHA and FEMA seem to be conspicuously absent from this meeting.
TASC is seeking an experienced Program Manager to join the Intelligence Solutions and Analytics (ISA) Sector. ISA provides specialized systems engineering, acquisition, and intelligence support to multiple Intelligence Community customers.
Scientific American (blog) Anthrax Blunder Reveals Deadly Potential of Accidents Scientific American (blog) Put another way: which is the more likely threat to public safety—a series of accidental releases of deadly organisms from the high-level…
Maryland life sciences innovators showing at BIO International
PathSensors, Baltimore / CEO Ted Olsen.
Kalon building $91m vaccine manufacturing facility in Texas for GSK partnership BioPharma-Reporter.com “Once we’re ready, which will be soon, BARDA can issue task orders to our center for up to $100m per year for biomanufacturing and development of…